15.43
+0.015(+0.10%)
Currency In USD
| Previous Close | 15.41 |
| Open | 15.66 |
| Day High | 15.74 |
| Day Low | 15.42 |
| 52-Week High | 16.66 |
| 52-Week Low | 6.38 |
| Volume | 204,896 |
| Average Volume | 1.7M |
| Market Cap | 1.49B |
| PE | -771.25 |
| EPS | -0.02 |
| Moving Average 50 Days | 12.81 |
| Moving Average 200 Days | 9.87 |
| Change | 0.02 |
If you invested $1000 in Avadel Pharmaceuticals plc (AVDL) 10 years ago, it would be worth $641.91 as of September 17, 2025 at a share price of $15.425. Whereas If you bought $1000 worth of Avadel Pharmaceuticals plc (AVDL) shares 5 years ago, it would be worth $2,609.98 as of September 17, 2025 at a share price of $15.425.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five ye
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025
GlobeNewswire Inc.
Sep 05, 2025 12:00 PM GMT
– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who w
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
GlobeNewswire Inc.
Sep 03, 2025 8:30 PM GMT
– Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter